Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

Key Takeaways AbbVie's oncology segment is projected to reach $1.71B in Q3 sales, up nearly 2% from last year.Strong Venclexta, Epkinly and Elahere sales may balance ongoing weakness in Imbruvica.New lung cancer drug Emrelis, approved in May, is expected to contribute modest early sales.AbbVie (ABBV) has built a substantial oncology franchise in recent years. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has expanded its offerings into solid tumors. Its latest offerings inclu ...